Journal of the European Academy of Dermatology and Venereology

Papers
(The H4-Index of Journal of the European Academy of Dermatology and Venereology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Comparison of performance of SCORTEN, ABCD‐10 and Re‐SCORTEN in a cohort of patients with Stevens–Johnson syndrome/toxic epidermal necrolysis222
Papillon‐Lefevre syndrome treated by acitretin: case report and cytokine profile156
Ichthyotic skin lesions of Conradi–Hünermann–Happle syndrome successfully treated with dupilumab145
Age matters: Rethinking SLNB's reliability in melanoma mortality prediction140
The European quest to reduce health risks associated with indoor tanning125
Announcement124
Aquagenic pruritus: A web‐based survey study exploring itch characteristics, therapeutic options and patient perspectives122
Successful treatment with tralokinumab in patients with atopic dermatitis and dupilumab‐induced psoriasis106
Electrochemotherapy with bleomycin for basal cell carcinomas: a systematic review98
Foreword91
Harlequin syndrome88
Clinical and trichoscopic aspects of scalp psoriasis: commentary to ‘Clinical and trichoscopic features in various forms of scalp psoriasis’ by F. Bruni et al.76
Announcement75
Associations between clinical variables and treatment regimens and hair density and calibre in female androgenetic alopecia patients: a retrospective study of 602 patients70
Evaluating for audiological differences in children with alopecia areata66
Use of SEM/EDX methods for the analysis of ambient particulate matter adhering to the skin surface63
High prevalence of extracutaneous involvement in ITG junctional epidermolysis bullosa62
Reply to ‘Burnout and professional quality of life in dermatologists’59
Two cases of cerebrovascular accidents following the induction dose of risankizumab59
Chronic nodular prurigo: Association between comorbidities, itch and quality of life58
Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia58
Acute urticaria management: Gaps, challenges and the need for further evidence58
Mepolizumab therapy for eosinophilic pustular folliculitis (Ofuji disease)57
Novel variant in WNT10A caused short anagen hair syndrome in a Chinese pedigree56
Difficulties in diagnosing dermatophytomas: Analysis of clinical and dermoscopic findings54
The impact of hand eczema54
Announcement53
Regulating sunbed use: Skin cancer risks linked to tanning beds49
Cryoinflation as an alternative treatment for fistulas in hidradenitis suppurativa49
The challenge of palmoplantar pustulosis therapy: Are Interleukin‐23 inhibitors an option?49
Fibrillar pattern as ultrasonographic progression biomarker of hidradenitis suppurativa49
Rosacea and upper gastrointestinal disorders: a case‐control study from a large, urban academic centre48
Predictors of malignancy in melanocytic lesions presenting as new lesions compared to baseline total body photography: A case–control study47
Use of therapeutic patient education tools for atopic dermatitis: A French national survey45
Assessment of the protective effect against air pollution‐induced skin pigmentation of an oral nutritional supplement containing antioxidants: A randomized, double‐blinded, placebo‐controlled study44
Psoriasis may increase the risk of lung cancer: a two‐sample Mendelian randomization study44
Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitl44
Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event 43
The risk of ultraviolet exposure for melanoma in Fitzpatrick skin types I–IV: A 20‐year systematic review with meta‐analysis for sunburns42
Pioneers in Dermatology and Venereology: An Interview with Professor Alain Taieb41
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group41
Issue Information41
Seroconversion and neutralizing antibodies production after completion of Pfizer‐BioNTech BNT 162b2 vaccination scheme among psoriatic patients receiving biological or topical treatment: A 41
Pigtail hairs in syphilitic alopecia41
0.077637910842896